Keros Therapeutics (NASDAQ:KROS) Sees Unusually-High Trading Volume – Should You Buy?

Keros Therapeutics, Inc. (NASDAQ:KROS) saw an uptick in trading volume on Friday . 923,607 shares were traded during mid-day trading, an increase of 110% from the previous session’s volume of 439,983 shares.The stock last traded at $19.67 and had previously closed at $18.43.

Analysts Set New Price Targets

Several brokerages have issued reports on KROS. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $85.67.

Keros Therapeutics Stock Performance

The company has a market capitalization of $762.75 million, a P/E ratio of -3.61 and a beta of 1.20. The company’s fifty day simple moving average is $59.11 and its 200-day simple moving average is $52.65.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.33) earnings per share. On average, sell-side analysts predict that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KROS. FMR LLC lifted its position in shares of Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares during the last quarter. Alkeon Capital Management LLC raised its stake in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after acquiring an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. lifted its position in Keros Therapeutics by 6.3% during the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after acquiring an additional 89,952 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP grew its holdings in Keros Therapeutics by 22.5% in the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after purchasing an additional 154,784 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.